Gabazza E C, Taguchi O, Yamakami T, Machishi M, Ibata H, Suzuki S
Third Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Japan.
Chest. 1993 Jan;103(1):196-200. doi: 10.1378/chest.103.1.196.
Clotting abnormalities are well-recognized complications that occur with high frequency in patients suffering from underlying malignant diseases. New and highly sensitive molecular markers of hemostasis, thrombin-antithrombin III complex (TAT III), D-dimer fragments (DD), and plasmin-alpha 2-antiplasmin complex (PIC) were measured in 58 consecutive lung cancer patients. Significant elevation in the blood concentrations of DD, PIC, and TAT was found in lung cancer patients, with either extensive or limited disease compared with values obtained in a healthy control group and in another group of patients with chronic obstructive pulmonary disease. Patients with distant metastasis exhibited significantly higher levels of these parameters as compared to those without metastasis. These data indicated that there was a subclinical activation of blood coagulation and fibrinolysis in lung cancer from the early clinical stages of the disease. In addition, there appeared to be different levels of clotting activation according to histologic type of tumor and response to chemotherapy.
凝血异常是患有潜在恶性疾病的患者中常见且广为人知的并发症。在58例连续的肺癌患者中检测了新的、高度敏感的止血分子标志物，即凝血酶 - 抗凝血酶III复合物（TAT III）、D - 二聚体片段（DD）和纤溶酶 - α2 - 抗纤溶酶复合物（PIC）。与健康对照组和另一组慢性阻塞性肺疾病患者的值相比，肺癌患者（无论疾病广泛或局限）的血液中DD、PIC和TAT浓度显著升高。与无转移的患者相比，远处转移的患者这些参数水平显著更高。这些数据表明，从疾病的早期临床阶段起，肺癌患者就存在血液凝固和纤维蛋白溶解的亚临床激活。此外，根据肿瘤的组织学类型和对化疗的反应，似乎存在不同程度的凝血激活。
